BCR-ABL1INS35 is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response

Tai Sung Lee; Wanlong Ma; Xi Zhang; Maher Albitar; Francis Giles; Jorge Cortes; Hagop Kantarjian

doi:10.1158/1535-7163.MCT-09-1116

BCR-ABL1^INS35 is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response

Tai Sung Lee
, Wanlong Ma
, Xi Zhang
, Maher Albitar
, Francis Giles
, Jorge Cortes
, Hagop Kantarjian

University of Minnesota
Quest Diagnostics Nichols Institute
University of Texas Health Science Center at San Antonio
Department of Cancer Biology

Research output: Contribution to a Journal (Peer & Non Peer) › Letter › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	772
Number of pages	1
Journal	Molecular Cancer Therapeutics
Volume	9
Issue number	3
DOIs	https://doi.org/10.1158/1535-7163.MCT-09-1116
Publication status	Published - Mar 2010
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1158/1535-7163.MCT-09-1116

Cite this

@article{c033d9c48f4345b2b65b5e9e290ce127,

title = "BCR-ABL1INS35 is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response",

author = "Lee, \{Tai Sung\} and Wanlong Ma and Xi Zhang and Maher Albitar and Francis Giles and Jorge Cortes and Hagop Kantarjian",

year = "2010",

month = mar,

doi = "10.1158/1535-7163.MCT-09-1116",

language = "English",

volume = "9",

pages = "772",

journal = "Molecular Cancer Therapeutics",

issn = "1535-7163",

publisher = "American Association for Cancer Research Inc.",

number = "3",

}

TY - JOUR

T1 - BCR-ABL1INS35 is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response

AU - Lee, Tai Sung

AU - Ma, Wanlong

AU - Zhang, Xi

AU - Albitar, Maher

AU - Giles, Francis

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2010/3

Y1 - 2010/3

UR - https://www.scopus.com/pages/publications/77949765312

U2 - 10.1158/1535-7163.MCT-09-1116

DO - 10.1158/1535-7163.MCT-09-1116

M3 - Letter

AN - SCOPUS:77949765312

SN - 1535-7163

VL - 9

SP - 772

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

IS - 3

ER -

BCR-ABL1INS35 is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response

UN SDGs

Access to Document

Other files and links

Cite this

BCR-ABL1^INS35 is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response